Literature DB >> 22738893

Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study.

Fatimah S Dawood1, A Danielle Iuliano, Carrie Reed, Martin I Meltzer, David K Shay, Po-Yung Cheng, Don Bandaranayake, Robert F Breiman, W Abdullah Brooks, Philippe Buchy, Daniel R Feikin, Karen B Fowler, Aubree Gordon, Nguyen Tran Hien, Peter Horby, Q Sue Huang, Mark A Katz, Anand Krishnan, Renu Lal, Joel M Montgomery, Kåre Mølbak, Richard Pebody, Anne M Presanis, Hugo Razuri, Anneke Steens, Yeny O Tinoco, Jacco Wallinga, Hongjie Yu, Sirenda Vong, Joseph Bresee, Marc-Alain Widdowson.   

Abstract

BACKGROUND: 18,500 laboratory-confirmed deaths caused by the 2009 pandemic influenza A H1N1 were reported worldwide for the period April, 2009, to August, 2010. This number is likely to be only a fraction of the true number of the deaths associated with 2009 pandemic influenza A H1N1. We aimed to estimate the global number of deaths during the first 12 months of virus circulation in each country.
METHODS: We calculated crude respiratory mortality rates associated with the 2009 pandemic influenza A H1N1 strain by age (0-17 years, 18-64 years, and >64 years) using the cumulative (12 months) virus-associated symptomatic attack rates from 12 countries and symptomatic case fatality ratios (sCFR) from five high-income countries. To adjust crude mortality rates for differences between countries in risk of death from influenza, we developed a respiratory mortality multiplier equal to the ratio of the median lower respiratory tract infection mortality rate in each WHO region mortality stratum to the median in countries with very low mortality. We calculated cardiovascular disease mortality rates associated with 2009 pandemic influenza A H1N1 infection with the ratio of excess deaths from cardiovascular and respiratory diseases during the pandemic in five countries and multiplied these values by the crude respiratory disease mortality rate associated with the virus. Respiratory and cardiovascular mortality rates associated with 2009 pandemic influenza A H1N1 were multiplied by age to calculate the number of associated deaths.
FINDINGS: We estimate that globally there were 201,200 respiratory deaths (range 105,700-395,600) with an additional 83,300 cardiovascular deaths (46,000-179,900) associated with 2009 pandemic influenza A H1N1. 80% of the respiratory and cardiovascular deaths were in people younger than 65 years and 51% occurred in southeast Asia and Africa.
INTERPRETATION: Our estimate of respiratory and cardiovascular mortality associated with the 2009 pandemic influenza A H1N1 was 15 times higher than reported laboratory-confirmed deaths. Although no estimates of sCFRs were available from Africa and southeast Asia, a disproportionate number of estimated pandemic deaths might have occurred in these regions. Therefore, efforts to prevent influenza need to effectively target these regions in future pandemics. FUNDING: None.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22738893     DOI: 10.1016/S1473-3099(12)70121-4

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  449 in total

1.  Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses.

Authors:  Yanmei Hu; Jiantao Zhang; Rami Ghassan Musharrafieh; Chunlong Ma; Raymond Hau; Jun Wang
Journal:  Antiviral Res       Date:  2017-08-02       Impact factor: 5.970

2.  Asthma and the flu: a tricky two-step.

Authors:  Richard M Locksley; John V Fahy
Journal:  Immunol Cell Biol       Date:  2014-04-01       Impact factor: 5.126

Review 3.  Global burden of influenza as a cause of cardiopulmonary morbidity and mortality.

Authors:  William A Fischer; Michelle Gong; Satish Bhagwanjee; Jonathan Sevransky
Journal:  Glob Heart       Date:  2014-10-31

4.  Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.

Authors:  Tülin Morçӧl; Brett L Hurst; E Bart Tarbet
Journal:  Vaccine       Date:  2017-07-14       Impact factor: 3.641

5.  The legacies of SARS - international preparedness and readiness to respond to future threats in the Western Pacific Region.

Authors:  John S Mackenzie; Angela Merianos
Journal:  Western Pac Surveill Response J       Date:  2013-07-02

6.  Trends in mortality from respiratory disease in Latin America since 1998 and the impact of the 2009 influenza pandemic.

Authors:  Maria de Fatima Marinho de Souza; Marc-Alain Widdowson; Airlane P Alencar; Vilma P Gawryszewski; Eduardo Aziz-Baumgartner; Rakhee Palekar; Joseph Breese; Po-Yung Cheng; Jarbas Barbosa; Ana M Cabrera; Andrea Olea; Arturo B Flores; David K Shay; Anthony Mounts; Otavio P Oliva
Journal:  Bull World Health Organ       Date:  2013-05-31       Impact factor: 9.408

7.  Naturally occurring mutations in the PA gene are key contributors to increased virulence of pandemic H1N1/09 influenza virus in mice.

Authors:  Yipeng Sun; Qi Xu; Ye Shen; Linqing Liu; Kai Wei; Honglei Sun; Juan Pu; Kin-Chow Chang; Jinhua Liu
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 8.  Case fatality risk of influenza A (H1N1pdm09): a systematic review.

Authors:  Jessica Y Wong; Heath Kelly; Dennis K M Ip; Joseph T Wu; Gabriel M Leung; Benjamin J Cowling
Journal:  Epidemiology       Date:  2013-11       Impact factor: 4.822

9.  Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets.

Authors:  Hae Jung Han; Min-Suk Song; Su-Jin Park; Han Yeul Byun; Norbert John C Robles; Suk-Hoon Ha; Young Ki Choi
Journal:  J Microbiol       Date:  2019-01-31       Impact factor: 3.422

10.  A Controlled Trial to Reduce the Risk of Human Nipah Virus Exposure in Bangladesh.

Authors:  Nazmun Nahar; Repon C Paul; Rebeca Sultana; Shariful Amin Sumon; Kajal Chandra Banik; Jaynal Abedin; Mohammad Asaduzzaman; Fernando Garcia; Susan Zimicki; Mahmudur Rahman; Emily S Gurley; Stephen P Luby
Journal:  Ecohealth       Date:  2017-09-13       Impact factor: 3.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.